154 related articles for article (PubMed ID: 18026153)
61. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research.
Hamadani M; Saber W; Ahn KW; Carreras J; Cairo MS; Fenske TS; Gale RP; Gibson J; Hale GA; Hari PN; Hsu JW; Inwards DJ; Kamble RT; Klein A; Maharaj D; Marks DI; Rizzieri DA; Savani BN; Schouten HC; Waller EK; Wirk B; Lazarus HM
Biol Blood Marrow Transplant; 2013 Apr; 19(4):625-31. PubMed ID: 23333532
[TBL] [Abstract][Full Text] [Related]
62. Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy.
Gopal AK; Pagel JM; Rajendran JG; Maloney DG; Appelbaum FR; Sorror ML; Sandmaier BM; Storb R; Press OW
Biol Blood Marrow Transplant; 2006 Jul; 12(7):697-702. PubMed ID: 16785058
[TBL] [Abstract][Full Text] [Related]
63. Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE; Dybedal I; Holte H; Heldal D; Torfoss D; Aurlien E; Lauritzsen GF; Fosså A; Lehne G; Baggerød E; Kvalheim G; Egeland T; Bishop MR; Fowler DH; Kolstad A
Bone Marrow Transplant; 2012 Dec; 47(12):1552-7. PubMed ID: 22522568
[TBL] [Abstract][Full Text] [Related]
64. Allogeneic stem cell transplantation with T cell-depleted grafts for lymphoproliferative malignancies.
Novitzky N; Thomas V
Biol Blood Marrow Transplant; 2007 Jan; 13(1):107-15. PubMed ID: 17222759
[TBL] [Abstract][Full Text] [Related]
65. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas.
Delioukina M; Zain J; Palmer JM; Tsai N; Thomas S; Forman S
Bone Marrow Transplant; 2012 Jan; 47(1):65-72. PubMed ID: 21358679
[TBL] [Abstract][Full Text] [Related]
66. Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan.
Fietz T; Uharek L; Gentilini C; Muessig A; Rieger K; Marinets O; Sandrock D; Munz DL; Glass B; Thiel E; Blau IW
Leuk Lymphoma; 2006 Jan; 47(1):59-63. PubMed ID: 16321828
[TBL] [Abstract][Full Text] [Related]
67. Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma.
Zoellner AK; Fritsch S; Prevalsek D; Engel N; Hubmann M; Reibke R; Rieger CT; Hellmuth JC; Haas M; Mumm F; Herold T; Ledderose G; Hiddemann W; Dreyling M; Hausmann A; Tischer J
Bone Marrow Transplant; 2015 May; 50(5):679-84. PubMed ID: 25642765
[TBL] [Abstract][Full Text] [Related]
68. Allogeneic transplantation after reduced-intensity conditioning with fludarabine-CY for both indolent and aggressive lymphoid malignancies.
Wondergem MJ; Dijkstra FS; Visser OJ; Zweegman S; Ossenkoppele GJ; Witte BI; Janssen JJ
Bone Marrow Transplant; 2014 Apr; 49(4):513-8. PubMed ID: 24419517
[TBL] [Abstract][Full Text] [Related]
69. Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma.
Clavert A; Le Gouill S; Brissot E; Dubruille V; Mahe B; Gastinne T; Blin N; Chevallier P; Guillaume T; Delaunay J; Ayari S; Saulquin B; Moreau A; Moreau P; Harousseau JL; Milpied N; Mohty M
Leuk Lymphoma; 2010 Aug; 51(8):1502-8. PubMed ID: 20583964
[TBL] [Abstract][Full Text] [Related]
70. Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies.
Yerushalmi R; Shem-Tov N; Danylesko I; Avigdor A; Nagler A; Shimoni A
Bone Marrow Transplant; 2015 Dec; 50(12):1526-35. PubMed ID: 26237166
[TBL] [Abstract][Full Text] [Related]
71. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma.
Shimoni A; Hardan I; Avigdor A; Yeshurun M; Raanani P; Ben-Bassat I; Nagler A
Br J Haematol; 2003 Aug; 122(3):457-64. PubMed ID: 12877674
[TBL] [Abstract][Full Text] [Related]
72. Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
McClune BL; Ahn KW; Wang HL; Antin JH; Artz AS; Cahn JY; Deol A; Freytes CO; Hamadani M; Holmberg LA; Jagasia MH; Jakubowski AA; Kharfan-Dabaja MA; Lazarus HM; Miller AM; Olsson R; Pedersen TL; Pidala J; Pulsipher MA; Rowe JM; Saber W; van Besien KW; Waller EK; Aljurf MD; Akpek G; Bacher U; Chao NJ; Chen YB; Cooper BW; Dehn J; de Lima MJ; Hsu JW; Lewis ID; Marks DI; McGuirk J; Cairo MS; Schouten HC; Szer J; Ramanathan M; Savani BN; Seftel M; Socie G; Vij R; Warlick ED; Weisdorf DJ
Biol Blood Marrow Transplant; 2014 Jul; 20(7):960-8. PubMed ID: 24641829
[TBL] [Abstract][Full Text] [Related]
73. Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP).
Gaudio F; Mazza P; Carella AM; Mele A; Palazzo G; Pisapia G; Carluccio P; Pastore D; Cascavilla N; Specchia G; Pavone V
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):35-40. PubMed ID: 30293754
[TBL] [Abstract][Full Text] [Related]
74. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.
Rule S; Cook G; Russell NH; Hunter A; Robinson S; Morley N; Sureda A; Patrick P; Clifton-Hadley L; Adedayo T; Kirkwood A; Peggs KS
Br J Haematol; 2019 Mar; 184(6):999-1005. PubMed ID: 30560573
[TBL] [Abstract][Full Text] [Related]
75. Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
Philippe L; Helias P; Puyraveau M; Boulahdour H; Deconinck E; Daguindau E
Bone Marrow Transplant; 2016 Aug; 51(8):1140-2. PubMed ID: 27042844
[No Abstract] [Full Text] [Related]
76. Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma.
Yano S; Mori T; Kanda Y; Kato J; Nakaseko C; Fujisawa S; Tomita N; Sakai R; Shono K; Saitoh T; Aotsuka N; Kobayashi N; Saito T; Takahashi S; Kanamori H; Okamoto S;
Bone Marrow Transplant; 2015 Oct; 50(10):1299-305. PubMed ID: 26168068
[TBL] [Abstract][Full Text] [Related]
77. Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
Chiesa C; Botta F; Coliva A; Maccauro M; Devizzi L; Guidetti A; Carlo-Stella C; Seregni E; Gianni MA; Bombardieri E
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1745-57. PubMed ID: 19455328
[TBL] [Abstract][Full Text] [Related]
78. Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.
Chiesa C; Botta F; Di Betta E; Coliva A; Maccauro M; Aliberti G; Bavusi S; Devizzi L; Guidetti A; Seregni E; Gianni AM; Bombardieri E
Cancer Biother Radiopharm; 2007 Feb; 22(1):113-20. PubMed ID: 17627419
[TBL] [Abstract][Full Text] [Related]
79. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome.
Robinson SP; Sureda A; Canals C; Russell N; Caballero D; Bacigalupo A; Iriondo A; Cook G; Pettitt A; Socie G; Bonifazi F; Bosi A; Michallet M; Liakopoulou E; Maertens J; Passweg J; Clarke F; Martino R; Schmitz N;
Haematologica; 2009 Feb; 94(2):230-8. PubMed ID: 19066328
[TBL] [Abstract][Full Text] [Related]
80. ⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
Gopal AK; Guthrie KA; Rajendran J; Pagel JM; Oliveira G; Maloney DG; Matesan MC; Storb RF; Press OW
Blood; 2011 Jul; 118(4):1132-9. PubMed ID: 21508413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
